Kaempferol Alleviates Murine Experimental Colitis by Restoring Gut Microbiota and Inhibiting the LPS-TLR4-NF-κB Axis
Intestinal microbiota dysbiosis is an established characteristic of ulcerative colitis (UC). Regulating the gut microbiota is an attractive alternative UC treatment strategy, considering the potential adverse effects of synthetic drugs used to treat UC. Kaempferol (Kae) is an anti-inflammatory and a...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.679897/full |
| _version_ | 1818656119093985280 |
|---|---|
| author | Yifan Qu Yifan Qu Xinyi Li Fengying Xu Shimin Zhao Xuemei Wu Yuzhen Wang Jiming Xie |
| author_facet | Yifan Qu Yifan Qu Xinyi Li Fengying Xu Shimin Zhao Xuemei Wu Yuzhen Wang Jiming Xie |
| author_sort | Yifan Qu |
| collection | DOAJ |
| description | Intestinal microbiota dysbiosis is an established characteristic of ulcerative colitis (UC). Regulating the gut microbiota is an attractive alternative UC treatment strategy, considering the potential adverse effects of synthetic drugs used to treat UC. Kaempferol (Kae) is an anti-inflammatory and antioxidant flavonoid derived from a variety of medicinal plants. In this study, we determined the efficacy and mechanism of action of Kae as an anti-UC agent in dextran sulfate sodium (DSS)-induced colitis mice. DSS challenge in a mouse model of UC led to weight loss, diarrhea accompanied by mucous and blood, histological abnormalities, and shortening of the colon, all of which were significantly alleviated by pretreatment with Kae. In addition, intestinal permeability was shown to improve using fluorescein isothiocyanate (FITC)–dextran administration. DSS-induced destruction of the intestinal barrier was also significantly prevented by Kae administration via increases in the levels of ZO-1, occludin, and claudin-1. Furthermore, Kae pretreatment decreased the levels of IL-1β, IL-6, and TNF-α and downregulated transcription of an array of inflammatory signaling molecules, while it increased IL-10 mRNA expression. Notably, Kae reshaped the intestinal microbiome by elevating the Firmicutes to Bacteroidetes ratio; increasing the linear discriminant analysis scores of beneficial bacteria, such as Prevotellaceae and Ruminococcaceae; and reducing the richness of Proteobacteria in DSS-challenged mice. There was also an evident shift in the profile of fecal metabolites in the Kae treatment group. Serum LPS levels and downstream TLR4-NF-κB signaling were downregulated by Kae supplementation. Moreover, fecal microbiota transplantation from Kae-treated mice to the DSS-induced mice confirmed the effects of Kae on modulating the gut microbiota to alleviate UC. Therefore, Kae may exert protective effects against colitis mice through regulating the gut microbiota and TLR4-related signaling pathways. This study demonstrates the anti-UC effects of Kae and its potential therapeutic mechanisms, and offers novel insights into the prevention of inflammatory diseases using natural products. |
| first_indexed | 2024-12-17T03:20:31Z |
| format | Article |
| id | doaj.art-8e9e377ea321422a9ac7f8ab048744d0 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-17T03:20:31Z |
| publishDate | 2021-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-8e9e377ea321422a9ac7f8ab048744d02022-12-21T22:05:32ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-07-011210.3389/fimmu.2021.679897679897Kaempferol Alleviates Murine Experimental Colitis by Restoring Gut Microbiota and Inhibiting the LPS-TLR4-NF-κB AxisYifan Qu0Yifan Qu1Xinyi Li2Fengying Xu3Shimin Zhao4Xuemei Wu5Yuzhen Wang6Jiming Xie7Inner Mongolia Clinical College, Inner Mongolia Medical University, Hohhot, ChinaClinical Laboratory, Inner Mongolia People’s Hospital, Hohhot, ChinaCollege of Life Science, Inner Mongolia Agricultural University, Hohhot, ChinaInner Mongolia Clinical College, Inner Mongolia Medical University, Hohhot, ChinaCollege of Life Science, Inner Mongolia Agricultural University, Hohhot, ChinaCollege of Life Science, Inner Mongolia Agricultural University, Hohhot, ChinaCollege of Life Science, Inner Mongolia Agricultural University, Hohhot, ChinaClinical Laboratory, Inner Mongolia People’s Hospital, Hohhot, ChinaIntestinal microbiota dysbiosis is an established characteristic of ulcerative colitis (UC). Regulating the gut microbiota is an attractive alternative UC treatment strategy, considering the potential adverse effects of synthetic drugs used to treat UC. Kaempferol (Kae) is an anti-inflammatory and antioxidant flavonoid derived from a variety of medicinal plants. In this study, we determined the efficacy and mechanism of action of Kae as an anti-UC agent in dextran sulfate sodium (DSS)-induced colitis mice. DSS challenge in a mouse model of UC led to weight loss, diarrhea accompanied by mucous and blood, histological abnormalities, and shortening of the colon, all of which were significantly alleviated by pretreatment with Kae. In addition, intestinal permeability was shown to improve using fluorescein isothiocyanate (FITC)–dextran administration. DSS-induced destruction of the intestinal barrier was also significantly prevented by Kae administration via increases in the levels of ZO-1, occludin, and claudin-1. Furthermore, Kae pretreatment decreased the levels of IL-1β, IL-6, and TNF-α and downregulated transcription of an array of inflammatory signaling molecules, while it increased IL-10 mRNA expression. Notably, Kae reshaped the intestinal microbiome by elevating the Firmicutes to Bacteroidetes ratio; increasing the linear discriminant analysis scores of beneficial bacteria, such as Prevotellaceae and Ruminococcaceae; and reducing the richness of Proteobacteria in DSS-challenged mice. There was also an evident shift in the profile of fecal metabolites in the Kae treatment group. Serum LPS levels and downstream TLR4-NF-κB signaling were downregulated by Kae supplementation. Moreover, fecal microbiota transplantation from Kae-treated mice to the DSS-induced mice confirmed the effects of Kae on modulating the gut microbiota to alleviate UC. Therefore, Kae may exert protective effects against colitis mice through regulating the gut microbiota and TLR4-related signaling pathways. This study demonstrates the anti-UC effects of Kae and its potential therapeutic mechanisms, and offers novel insights into the prevention of inflammatory diseases using natural products.https://www.frontiersin.org/articles/10.3389/fimmu.2021.679897/fullkaempferolulcerative colitisgut microbiotalipopolysaccharideTLR4NF-κB |
| spellingShingle | Yifan Qu Yifan Qu Xinyi Li Fengying Xu Shimin Zhao Xuemei Wu Yuzhen Wang Jiming Xie Kaempferol Alleviates Murine Experimental Colitis by Restoring Gut Microbiota and Inhibiting the LPS-TLR4-NF-κB Axis Frontiers in Immunology kaempferol ulcerative colitis gut microbiota lipopolysaccharide TLR4 NF-κB |
| title | Kaempferol Alleviates Murine Experimental Colitis by Restoring Gut Microbiota and Inhibiting the LPS-TLR4-NF-κB Axis |
| title_full | Kaempferol Alleviates Murine Experimental Colitis by Restoring Gut Microbiota and Inhibiting the LPS-TLR4-NF-κB Axis |
| title_fullStr | Kaempferol Alleviates Murine Experimental Colitis by Restoring Gut Microbiota and Inhibiting the LPS-TLR4-NF-κB Axis |
| title_full_unstemmed | Kaempferol Alleviates Murine Experimental Colitis by Restoring Gut Microbiota and Inhibiting the LPS-TLR4-NF-κB Axis |
| title_short | Kaempferol Alleviates Murine Experimental Colitis by Restoring Gut Microbiota and Inhibiting the LPS-TLR4-NF-κB Axis |
| title_sort | kaempferol alleviates murine experimental colitis by restoring gut microbiota and inhibiting the lps tlr4 nf κb axis |
| topic | kaempferol ulcerative colitis gut microbiota lipopolysaccharide TLR4 NF-κB |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2021.679897/full |
| work_keys_str_mv | AT yifanqu kaempferolalleviatesmurineexperimentalcolitisbyrestoringgutmicrobiotaandinhibitingthelpstlr4nfkbaxis AT yifanqu kaempferolalleviatesmurineexperimentalcolitisbyrestoringgutmicrobiotaandinhibitingthelpstlr4nfkbaxis AT xinyili kaempferolalleviatesmurineexperimentalcolitisbyrestoringgutmicrobiotaandinhibitingthelpstlr4nfkbaxis AT fengyingxu kaempferolalleviatesmurineexperimentalcolitisbyrestoringgutmicrobiotaandinhibitingthelpstlr4nfkbaxis AT shiminzhao kaempferolalleviatesmurineexperimentalcolitisbyrestoringgutmicrobiotaandinhibitingthelpstlr4nfkbaxis AT xuemeiwu kaempferolalleviatesmurineexperimentalcolitisbyrestoringgutmicrobiotaandinhibitingthelpstlr4nfkbaxis AT yuzhenwang kaempferolalleviatesmurineexperimentalcolitisbyrestoringgutmicrobiotaandinhibitingthelpstlr4nfkbaxis AT jimingxie kaempferolalleviatesmurineexperimentalcolitisbyrestoringgutmicrobiotaandinhibitingthelpstlr4nfkbaxis |